Loading news...
NeoGenomics, Inc. (NASDAQ: NEO - Get Free Report) has received a consensus recommendation of "Hold" from the thirteen brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have given a hold recommendation, five have given a buy recommendation and one has given
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial markets on Feb. 17, 2026.
NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform, leveraging deep relationships with community oncologists. NEO's clinical services revenue grew 18% YoY in Q3 2025, with high-value Next Generation Sequencing now nearly one-third of clinical revenue and outpacing market growth. The upcoming RaDaR ST launch in Q1 2026 positions NEO as a fast follower in the $20B MRD market, capitalizing on its established distribution and workflow integration.
Campbell and CO Investment Adviser LLC lowered its position in NeoGenomics, Inc. (NASDAQ: NEO) by 60.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,487 shares of the medical research company's stock after selling 46,288 shares during
NEW YORK--(BUSINESS WIRE)---- $BETR #AI--Better Home & Finance Holding Company (NASDAQ: BETR) (“Better.com”), the leading AI-native home finance company and the first fintech to fund more than $100 billion in loan volume, celebrates the one-year anniversary of its partnership with NEO Home Loans (“NEO”) and proudly announces significant gains in production efficiency and cost to originate through its advisor-led distributed retail channel, NEO powered by Better. This monumental growth demonstrates the me.
NeoGenomics (NASDAQ: NEO - Get Free Report) and AstraZeneca (NASDAQ: AZN - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings. Insider and Institutional Ownership 98.5% of NeoGenomics shares are held
NeoGenomics, Inc. (NEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
DUBLIN, Jan. 13, 2026 /PRNewswire/ -- AerCap Holdings N.V. ("AerCap" or the "Company") (NYSE: AER) today announced it has signed purchase and leaseback agreements with Virgin Atlantic for six new Airbus A330-900 aircraft, from Virgin Atlantic's open orderbook.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company's Chief Financial Officer.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of John P. “Jack” Kenny to its Board of Directors.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced that Natera has voluntarily withdrawn its appeal in ongoing RaDaR patent litigation.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present data on its RaDaR 1.0 assay for molecular residual disease detection at the 2025 San Antonio Breast Cancer Symposium.
DUBLIN , Dec. 9, 2025 /PRNewswire/ -- AerCap Holdings N.V. ("AerCap" or the "Company") (NYSE: AER) today announced it has signed lease agreements for two new Airbus A321neo aircraft with My Freighter, an Uzbekistan-based cargo airline that also operates charter and scheduled passenger services as Centrum Air.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present new data at ASH on how comprehensive genomic profiling supports diagnosis and treatment decisions in myeloid malignancies.
PARIS--(BUSINESS WIRE)--TotalEnergies has signed an agreement with NEO NEXT Energy Limited (NEO NEXT) under which TotalEnergies will merge its Upstream business with NEO NEXT and become the leading shareholder in the expanded NEO NEXT, which will be renamed NEO NEXT+, with a 47.5% ownership. After completion of the transaction, NEO NEXT+ will: be jointly owned by TotalEnergies (47.5%), HitecVision (28.875%) and Repsol UK (23.625%) and encompass a large and diverse asset portfolio including nota.
Shares of NeoGenomics, Inc. (NASDAQ: NEO - Get Free Report) have earned an average rating of "Hold" from the sixteen research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company.
Neo Performance Materials Inc. ( NEO:CA ) Q3 2025 Earnings Call November 14, 2025 10:00 AM EST Company Participants Karen Murray Rahim Suleman - CEO, President & Director Jonathan Baksh - Executive VP & CFO Conference Call Participants Daniel Harriman - Sidoti & Company, LLC Nicholas Boychuk - Cormark Securities Inc., Research Division Ian Gillies - Stifel Nicolaus Canada Inc., Research Division Presentation Operator Good morning, and welcome to the Neo Performance Materials Third Quarter 2025 Earnings Conference Call. For opening remarks and introduction, let me turn the call over to Karen Murray, General Counsel for Neo.
CALABASAS, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced the completion of full patient enrollment in its ongoing NEO100-1 Phase 2a clinical trial.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Stephens Annual Investment Conference and the Piper Sandler 37th Annual Healthcare Conference.